Salmon calcitonin and calcium in the treatment of male osteoporosis: The effect on bone mineral density

Wiener Klinische Wochenschrift

Volumn 109, Issue 8, 1997, Pages 270-274

  Erlacher, Ludwig ^a   Kettenbach, Joachim ^a   Kiener, Hans ^a   Graninger, Winfried ^a   Kainberger, Franz ^a   Pietschmann, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

bone mineral density; calcitonin; male osteoporosis

Indexed keywords

CALCITONIN; CALCIUM;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; OSTEOPOROSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANALGESICS; BONE DENSITY; CALCITONIN; CALCIUM; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES;

EID: 0030915878     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Adachi JD, Bensen WG, Hodsman AB (1993) Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 22: 375-384
2. Burckhardt P (1992) Treatment of osteoporosis. Curr Opin Rheumatol 4: 402
3. Chambers TJ, Dunn CJ (1983) Pharmacological control of osteoclastic motility. Calcif Tissue Int 35: 566-579
4. Chesnut III CH (1992) Review of calcitonin-present: current status of calcitonin as a therapeutic agent. Bone and Mineral 16:211-212
5. Christiansen C (1992) Prevention and treatment of osteoporosis: a review of current modalities. Bone 13: 35-39
6. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in post-menopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82: 1268-1274
7. Farley JR, Tarbaux NM, Hall SL, Linkhart TA, Baylink DJ (1988) The anti-bone-resportive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation. Endocrinology 123: 159-167
8. Farley JR, Hall SL, Herring S, Tarbaux NM (1992) Two biochemical indices of mouse bone formation are increased, in vivo, in response to calcitonin. Calcif Tissue Int 50: 67-73
9. Feldmann RS, Krieger NS, Tashjian AH (1980) Effects of parathyroid hormone and calcitonin on osteoclast formation in vitro. Endocrinology 107: 1137-1143
10. Gennari C, Agnusdei D, Camporeale A (1993) Long-term treatment with calcitonin in osteoporosis. Horm Metab Res 25: 484-485
11. Gennari C, Passeri M, Chierichetti SM, Piolini M (1983) Side-effects of synthetic salmon and human calcitonin. Lancet 1: 594-595
12. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33: 295-303
13. Gudman Hoyer E (1994) The clinical significance of disaccharide maldigestion. Am J Clin Nutr 59 [Suppl] 3: 735S-741S
14. Jackson JA, Kleerekoper M, Parfitt AM, Rao DS, Villanueva AR, Frame B (1987) Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 65: 53-58
15. Kanis JA, Pitt FA (1992) Epidemiology of osteoporosis. Bone 13 [Suppl] 1:S7-S15
16. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, et al (1994) Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 6: 35-41
17. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al (1995) Effect of oral alendronat on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443
18. McFarlane XA, Bhalla AK, Reeves DE, Morgan LM, Robertson DA (1995) Osteoporosis in treated adult coeliac disease. Gut 36: 710-714
19. Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, et al (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38: 3-8
20. Niewoehner CB (1993) Osteoporosis in men. Postgraduate Med 8: 59-70
21. Orme SM, Simpson M, Stewart SP, Oldroyd B, Westmacott CF, Smith MA, Belchetz PE (1994) Comparison of changes in bone mineral in idiopathic and secon dary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. Clin Endocrinol Oxf 41: 245-250
22. Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305: 556-561
23. Philip WJ, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS (1995) Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 88: 635-640
24. Reginster JY (1991) Effect of calcitonin on bone mass and fracture rates. Am J Med 91 [Suppl] 5B: 19S-22S
25. Reginster JY (1993) Calcitonin for prevention and treatment of osteoporosis. Am J Med 95 [Suppl] 5A: 44S-47S
26. Resch H, Pietschmann P, Krexner E, Willvonseder R (1991) Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon. European Heart J 12: 439-441
27. Ringe JD, Dorst AJ (1994) Osteoporose bei Männern. Dtsch Med Wochenschr 119: 943-947
28. Sambrook PN, Kelly PJ, Keogh AM, Macdonald P, Spratt P, Freund J, Eisman JA (1994) Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant 13: 116-120
29. Seeman E, Melton III LJ, O'Fallon WM, Riggs BL (1983) Risk factors for spinal osteoporosis in men. Am J Med 75: 977-983
30. Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99: 235-242
31. Szücs J, Horvath C, Kollin E, Szathmari M, Hollo I (1992) Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcif Tissue Int 50: 7-10
32. Vogelsang H, Ferenci P, Frotz S, Meryn S, Gangl A (1988) Acidic colonic microclimate-possible reason for false negative hydrogen breath tests. Gut 29: 21-26
33. Wallach S, Farley JR, Baylink DJ, Brenner-Gati L (1993) Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int 52: 335